8-K current report · filed Nov 9, 2026

ArriVent BioPharma, Inc. (AVBP) 8-K Current Report: November 9, 2026

Item 2.02Item 5.02Item EX-99.1AVBP overview

Short answer

ArriVent BioPharma, Inc. (AVBP) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.

ArriVent BioPharma, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Investor-relevant figures and management commentary contained in Exhibit 99.1 press release

Item 5.02 · Departure/Election of Directors or Officers

  • Stuart Lutzker, President of R&D and director, retires effective December 1, 2026
  • Departure not related to disagreements, reducing apparent governance or operational conflict risk
  • One-time retirement payment of $428,438.21, subject to duties, restrictive covenants, and claims release
  • Chief Medical Officer Priti Patel assumes R&D leadership December 1, 2026
  • Leadership continuity supported by Patel’s oncology, hematology, and clinical-development background

Item EX-99.1 · Exhibit EX-99.1

  • FURVENT missed its primary PFS endpoint, weakening firmonertinib’s near-term approval case despite 11.0-month PFS vs 9.5 months and ORR 60% vs 33%
  • ALPACCA Phase 3 enrollment remains on track, preserving the lead program’s potential in EGFR PACC-mutant NSCLC
  • ARR-217 showed preliminary ORR 44.8% and DCR 93.1% at 6 mg/kg, supporting continued ADC development in colorectal cancer
  • Cash and investments $393.2 million, expected to fund operations to mid-2028, reducing near-term financing risk
  • Nine-month net loss $133.5 million, with G&A rising to $28.3 million from $17.5 million and R&D at $118.9 million

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ArriVent BioPharma, Inc. 8-K filings

Get the next AVBP 8-K as it lands

Follow AVBP for push alerts, or ask the research agent what this filing means.